Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-28 5:31 pm Purchase | 2024-10-29 | 13G | ERNEXA THERAPEUTICS INC ERNA | Freebird Partners LP | 13,698 9.990% | 10,889 (+387.65%) | Filing History |
| 2024-01-31 07:05 am Purchase | 2023-12-31 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | John D. Halpern | 550,894 9.990% | 98,611 (+21.80%) | Filing History |
| 2024-01-19 10:31 am Purchase | 2023-12-31 | 13G | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 1,601 9.990% | 115 (+7.74%) | Filing History |
| 2023-12-22 12:05 pm Unchanged | 2023-12-14 | 13D | ERNEXA THERAPEUTICS INC ERNA | Charles Cherington | 3,233 19.990% | 0 (Unchanged) | Filing History |
| 2023-12-20 3:24 pm Purchase | 2023-12-14 | 13G | ERNEXA THERAPEUTICS INC ERNA | IAF, LLC | 1,539 9.990% | 1,539 (New Position) | Filing History |
| 2023-09-08 06:07 am Unchanged | 2023-07-06 | 13G | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 1,486 9.900% | 0 (Unchanged) | Filing History |
| 2023-09-07 5:26 pm Purchase | 2023-07-13 | 13D | ERNEXA THERAPEUTICS INC ERNA | Charles Cherington | 3,233 19.990% | 1,720 (+113.68%) | Filing History |
| 2023-08-28 4:57 pm Purchase | 2023-04-03 | 13G | ERNEXA THERAPEUTICS INC ERNA | Purchase Capital LLC | 748 5.000% | 748 (New Position) | Filing History |
| 2023-07-26 5:05 pm Purchase | 2023-04-03 | 13D | ERNEXA THERAPEUTICS INC ERNA | Nicholas Jason Singer | 1,486 9.990% | 436 (+41.52%) | Filing History |
| 2023-07-20 7:52 pm Purchase | 2023-07-14 | 13G | ERNEXA THERAPEUTICS INC ERNA | Freebird Partners LP | 2,809 19.990% | 949 (+51.02%) | Filing History |
| 2023-04-04 5:14 pm Purchase | 2023-04-03 | 13G | ERNEXA THERAPEUTICS INC ERNA | Freebird Partners LP | 1,860 12.600% | 1,133 (+155.85%) | Filing History |
| 2023-03-06 4:07 pm Sale | 2022-12-31 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | DENNY GEORGE P III | 460,413 15.600% | -4,447,579 (-90.62%) | Filing History |
| 2023-01-31 4:05 pm Purchase | 2023-01-31 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | John D. Halpern | 452,283 8.800% | 1,117 (+0.25%) | Filing History |
| 2022-12-20 4:30 pm Sale | 2022-12-02 | 13D | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Nicholas Jason Singer | 393,766 7.670% | -1,701,234 (-81.20%) | Filing History |
| 2022-12-14 4:30 pm Sale | 2022-12-02 | 13D | ERNEXA THERAPEUTICS INC ERNA | Charles Cherington | 1,513 11.050% | -14,256 (-90.41%) | Filing History |
| 2022-12-05 5:20 pm Sale | 2022-12-02 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | John D. Halpern | 451,166 8.800% | -4,296,079 (-90.50%) | Filing History |
| 2022-12-02 5:01 pm Purchase | 2022-12-02 | 13G | ERNEXA THERAPEUTICS INC ERNA | Freebird Partners LP | 727 5.300% | 727 (New Position) | Filing History |
| 2022-03-16 4:30 pm Sale | 2022-03-09 | 13D | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Charles Cherington | 5,913,365 11.400% | -399,932 (-6.33%) | Filing History |
| 2022-02-16 5:15 pm Sale | 2021-12-31 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Nicholas Jason Singer | 2,095,000 4.000% | -1,696,983 (-44.75%) | Filing History |
| 2021-08-27 5:26 pm Purchase | 2021-08-27 | 13G | BROOKLYN IMMUNO THERAPEUTICS L ERNAW | Factor Bioscience Inc. | 4,670,980 9.000% | 4,670,980 (New Position) | Filing History |